Gastric Cancer
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 7, 2005; 11(21): 3204-3211
Published online Jun 7, 2005. doi: 10.3748/wjg.v11.i21.3204
Figure 1
Figure 1 Transfection rates of rAd in gastric cancer cells. A: MOI = 20; B: MOI = 50; C: MOI = 100.
Figure 2
Figure 2 Flow cytometric analysis of B7-1 gene expression. A: SGC-7901; B: SGC-7901/FB-11.
Figure 3
Figure 3 RT-PCR analysis of FasL expression in SGC-7901/FB-11 and SGC-7901. A: SGC-7901/FB-11; B: SGC-7901; C: DNA Marks.
Figure 4
Figure 4 Proliferation inhibition of gastric cancer cell lines. ■: SGC-7901; ○: SGC-7901L/FasL; ●: SGC-7901/FB-11; □: PBS.
Figure 5
Figure 5 Apoptosis of SGC-7901 cells stained with Hoechst 33342 induced by FB-11 (×400). A: SGC-7901/GFP cells; B: SGC-7901/FB-11 cells.
Figure 6
Figure 6 DNA fragmentation of SGC-7901 cells induced by FB-11. A: DNA Marks; B: SGC-7901/FB-11; C: MGC-803/FB-11; D: BGC-823/FB-11; E: SGC-7901.
Figure 7
Figure 7 Tumorigenicity of FB-11-transfected gastric cancer cells and tumor size in preventive and control groups. ●: FB-11 preventive group; ■: control group.
Figure 8
Figure 8 FB-11-mediated protective immunity. ■: SGC-7901/FB-11-sensitized mice group; ●: SGC-7901 mice group (not sensitized with SGC-7901/FB-11).
Figure 9
Figure 9 Cytotoxicity of abdominal lymphocyte infiltration against tumor cells induced by FB-11. A: cytotoxicity of SGC-7901/FB-11-induced abdominal lymphocyte infiltration against SGC-7901/FB-11 cells (n = 4); B: cytotoxicity of SGC-7901/FB-11-induced abdominal lymphocyte infiltration against SGC-7901 cells (n = 4); C: cytotoxicity of SGC-7901-induced abdominal lymphocyte infiltration against SGC-7901 cells (n = 4).
Figure 10
Figure 10 Cytotoxicity of spleen cells against tumor cells induced by FB-11. A: cytotoxicity of SGC-7901/FB-11-induced spleen cells against SGC-7901/FB-11 cells (n = 4); B: Cytotoxicity of SGC-7901/FB-11-induced spleen cells against SGC-7901 cells (n = 4); C: Cytotoxicity of SGC-7901-induced spleen cells against SGC-7901 cells (n = 4).